Furthermore, the results indicated that miR-383 may exert its tumor-suppressive effect by inhibiting the PI3K/AKT/mTOR pathway.52 Studies have proven that miR-383 is downregulated in prostate cancer, essential in determining tumor initiation potential and affecting metastasis by directly regulating CD44. Here, MTOR is linked to prostate carcinoma.